Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6184834 | Gynecologic Oncology | 2015 | 6 Pages |
Abstract
After fertility-sparing surgery and modern cisplatin-based chemotherapy, fertility is preserved in most MOGCT survivors though dependent on the number of cycles. AMH's role as a biomarker of gonadal function seems promising but requires further research.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
O. Solheim, C.G. Tropé, E. Rokkones, J. Kærn, T. Paulsen, H.B. Salvesen, B. Hagen, A.B. Vereide, S.D. FossÃ¥,